


In the Claims:

Please amend the claims according to the claim listing below.

1. (original) A compound of Formula (I):



wherein:

X is NH or O;

R₁ is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

R₂ is selected from the group consisting of H, halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl; or R₂ is absent;

— is a single bond when R₂ is present, or — is a double bond when R₂ is absent; and

Ring A is a 5, 6 or 7-membered carbocyclic ring or a 5, 6 or 7-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, hydroxy, thioxy, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, C₂₋₈ dialkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₅ cycloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

2. (original) The compound according to claim 1 wherein:

X is NH;

R₁ is H or hydroxy;

R₂ is H or absent;


— is a single bond when R₂ is H, or — is a double bond when R₂ is absent;

and

Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

3. (original) The compound according to claim 1 having Formula (If):



(If)


wherein:

R₁ is H or hydroxy; and

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.

4. (original) The compound according to claim 1 having Formula (Ih):




(Ih)

wherein:

Ring A is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or

a pharmaceutically acceptable salt, solvate or hydrate thereof.


5. (original) The compound according to claim 1 having Formula (Ih):



wherein:

Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof..

6. (original) The compound according to claim 1 having Formula (Ih):



wherein:

Ring A is substituted with 1 or 2 substituents selected from the group consisting of halogen, *n*-propyl, *n*-butyl, C₁₋₄ alkoxy and C₃₋₅ cycloalkyl; or
a pharmaceutically acceptable salt, solvate or hydrate thereof.

7. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

9. (original) The compound according to claim 1 that is 6-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

10. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

11. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
12. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-4H-furo[3,4-c]pyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
13. (original) The compound according to claim 1 that is 5-Ethyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
14. (original) The compound according to claim 1 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
15. (original) The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
16. (original) The compound according to claim 1 that is 5-Methyl-3-(1H-tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
17. (original) The compound according to claim 1 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
18. (original) The compound according to claim 1 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
19. (original) The compound according to claim 1 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

20. (original) The compound according to claim 1 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

21. (original) The compound according to claim 1 that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. (original) The compound according to claim 1 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

23. (original) The compound according to claim 1 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazol-6-ol or a pharmaceutically acceptable salt, solvate or hydrate thereof.

24. (original) The compound according to claim 1 that is 5-Methoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

25. (original) The compound according to claim 1 that is 5,5-Difluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

26. (original) The compound according to claim 1 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

27. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 26~~ claim 1 in combination with a pharmaceutically acceptable carrier.

28. (currently amended) A method of treatment of a metabolic-related disorder comprising administering to an individual in need of such treatment a therapeutically-effective amount of a compound according to ~~any one of claims 1 to 26~~ claim 1.

29. (currently amended) The method according to claim 27 ~~28~~ wherein said metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

30. (currently amended) The method according to claim 27 ~~28~~ wherein said metabolic-related disorder is atherosclerosis.

31. (currently amended) A method of raising HDL in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to ~~any one of claims 1 to 26~~ claim 1.

32.-40. (canceled)

41. (currently amended) A method of producing a pharmaceutical composition comprising admixing a compound according to ~~any one of claims 1 to 26~~ claim 1 and a pharmaceutically acceptable carrier.

42. (new) The compound of claim 1 wherein Ring A is a 5, 6 or 7 membered heterocyclic ring containing one group selected from O, S, S(O), and S(O)₂.